Werewolf Therapeutics (HOWL) Shares Outstanding (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Shares Outstanding (Entity) of $48.6 million for Q2 2026, up 7.2% year-over-year from $45.3 million in Q2 2025, and little changed on a QoQ basis from $48.6 million in Q1 2026.
Werewolf Therapeutics (HOWL) Shares Outstanding (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $48.6 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $48.6 million, up 7.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $48.6 million (up 7.2% YoY), and the FY2025 annual result was $48.6 million, up 8.41% from the prior year.
- Shares Outstanding (Entity) steadied at $48.6 million in Q2 2026, from $48.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $48.6 million in Q2 2026 and troughed at $27.7 million in Q1 2022.
- A 5-year average of $40.2 million and a median of $43.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2022, when Shares Outstanding (Entity) soared 2150.12%; it then grew 3.57% in 2025.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $31.5 million in 2022, then increased by 24.09% to $39.1 million in 2023, then advanced by 14.63% to $44.8 million in 2024, then increased by 8.41% to $48.6 million in 2025, then grew by 0.0% to $48.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $48.6 million in Q2 2026, $48.6 million in Q1 2026, and $48.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 48.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.60 Mn |
| Mar 31, 2026 | 48.60 Mn |
| Dec 31, 2025 | 46.02 Mn |
| Sep 30, 2025 | 45.80 Mn |
| Jun 30, 2025 | 44.98 Mn |
| Mar 31, 2025 | 44.83 Mn |
| Dec 31, 2024 | 43.33 Mn |
| Sep 30, 2024 | 43.70 Mn |
| Jun 30, 2024 | 43.52 Mn |
| Mar 31, 2024 | 41.61 Mn |
| Dec 31, 2023 | 35.65 Mn |
| Sep 30, 2023 | 35.65 Mn |
| Jun 30, 2023 | 35.56 Mn |
| Mar 31, 2023 | 34.79 Mn |
| Dec 31, 2022 | 28.86 Mn |
| Sep 30, 2022 | 29.76 Mn |
| Jun 30, 2022 | 27.52 Mn |
| Mar 31, 2022 | 27.39 Mn |
| Dec 31, 2021 | 18.46 Mn |
| Sep 30, 2021 | 27.19 Mn |